EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable hilar cholangiocarcinoma

Wenbo Yang, Yinghao Wang, Li Xiao, Fei Liu, Jianxi Zhou, Yunchuan Sun

Frontiers in Oncology · 05.08.2026 · 16

DOI: 10.3389/fonc.2026.1909866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 05.08.2026. Verfasst von Wenbo Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head, Neck and Thoracic Medical Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine-Hebei, Cangzhou, Heb…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of 192 Ir brachytherapy combined with external beam radiotherapy (EBRT) and biliary stenting in patients with unresectable hilar cholangiocarcinoma. Methodology Clinical data of 62 patients with unresectable hilar cholangiocarcinoma were retrospectively analyzed. All patients received concurrent chemoradiotherapy plus percutaneous biliary stenting. Among them, 32 patients ( 192 Ir group) additionally received 192 Ir brachytherapy, and 30 patients (EBRT group) received EBRT alone. Survival outcomes were analyzed using the Kaplan–Meier method.

Results

At 3 months after treatment, the objective response rate was 93.8% in the 192 Ir group and 70.0% in the EBRT group. Median progression-free survival was 11.2 months vs 8.6 months (P = 0.032), and median overall survival was 14.5 months vs 12.2 months (P = 0.361). Liver function parameters and CA19–9 levels decreased in both groups, with significantly lower levels in the 192 Ir group at 3 months. Adverse events were tolerable in both groups.

Conclusion

192 Ir brachytherapy plus EBRT and biliary stenting may improve short-term tumor response and progression-free survival in unresectable hilar cholangiocarcinoma, with tolerable toxicity.

Schlagwörter

Stichwörter der Autor:innen

biliary stentingbrachytherapyexternal beam radiotherapyhilar cholangiocarcinomairidium-192

Autor:innen und Institutionen

  • Department of Head, Neck and Thoracic Medical Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine-Hebei, Cangzhou, Hebei, China.
  • Department of Second General Surgery, Hengshui Fifth People's Hospital, Hengshui, Hebei, China.

Zitieren

APA

Yang, W., Wang, Y., Xiao, L., Liu, F., Zhou, J., & Sun, Y. (2026). 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable hilar cholangiocarcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1909866

Vancouver

Yang W, Wang Y, Xiao L, Liu F, Zhou J, Sun Y. 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable hilar cholangiocarcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1909866

BibTeX
@article{Yang2026,
  author = {Yang, Wenbo and Wang, Yinghao and Xiao, Li and Liu, Fei and Zhou, Jianxi and Sun, Yunchuan},
  title = {192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable hilar cholangiocarcinoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1909866}
}
Kostenlos starten →